3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
7
Myeloproliferative Disorders
3
Myelodysplastic Syndromes
2
Leukemia, Monocytic, Acute
2
Sarcoma, Kaposi
1
Rectal Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
HIV Infections
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Cancer Metastatic
1
Acquired Immunodeficiency Syndrome
1
Interventions
Fulvestrant
5
Letrozole
3
Capecitabine
3
ribociclib
2
exemestane
2
dalpiciclib
2
apatinib
2
Irinotecan
2
Gemcitabine
2
Anastrozole
2
tusamitamab ravtansine
1
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pegfilgrastim
1
palbociclib
1
margetuximab
1
irinotecan sucrosofate
1
fluzoparib
1
abemaciclib
1
Vinorelbine
1
Trastuzumab
1
Tamoxifen
1
Paclitaxel
1
Liposomes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Cancer Metastatic
×
Liposomes
×
Clear all
NCT03328884
2025-04-23
Phenomenal
MedSIR
Phase 2
Completed
55 enrolled